Press Releases

Tower launches “game-changing” solution for the transport of ultra cold temperature-critical pharmaceuticals

Tower launches “game-changing” solution for the transport of ultra cold temperature-critical pharmaceuticals

Curebase’s Enhanced Telemedicine Feature Expands Patient Access to Edesa Biotech Derm Study

Curebase’s Enhanced Telemedicine Feature Expands Patient Access to Edesa Biotech Derm Study

VIDA Diagnostics to Address Overcoming Pervasive Challenges in Respiratory Clinical Trials During 12/8 Webinar

A 12/8 webinar with leading pulmonary disease clinician Dr. Mario Castro will address the rise of imaging in respiratory clinical trials, something worth hearing considering the uncertainty of the long-term impact of COVID-19 and other factors.

Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research. The exclusive global contract aims to maximize opportunities in RNA drug discovery and mRNA vaccine manufacture through Noxopharm’s wholly owned subsidiary, Pharmorage.

Formedix Launches Community Forum and Resource Hub to Support Clinical Trial Industry

Formedix has announced the launch of a community forum and resource hub to allow contract research organizations and pharmaceutical companies using the ryze clinical metadata repository.

BOC Sciences Adds Phosphoramidites to Its Nucleotide Product Portfolio for Oligonucleotide Synthesis

T,C&A Lab Offers Glass Testing to Reduce Risk and Validate Glass Performance

CD Formulation Assists in Solving Dosage Form Development Problems

Clinical Ink Ranked Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

Clinical Ink today announced it ranked on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.

Thermo Fisher Scientific Advances Proteomics Through Select Collaborations and New Analytical Instrument Solutions

Thermo Fisher Scientific has announced a series of co-marketing agreements, in addition to a new chromatography system and acquisition, to support scientists in driving their proteomics research forwards.

Emmes and MedGenome Launch Genomics Strategic Partnership Focused on Advancing Rare Disease Research

Biotium expands multiplexing options for probe-based qPCR with unique red qPCR dye

Biotium has announced the release of EvaRuby™ Dye for qPCR and HRM®.

Vanessa Biotech receives approval from Ghana FDA to proceed with Cholera Phase II Clinical Trial

About Vanessa Biotech Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Tesis Labs Announces Name Change to Tesis Biosciences

Tesis Labs Announces Name Change to Tesis Biosciences

CPhI Pharma Index reaches record high as pharma confidence in growth rises in all markets

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Today, IBM Research and Arctoris, an Oxford-based technology company operating a fully automated drug discovery platform, announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery.

BioIVT’s Biospecimen Repository and Clinical Database Prove Valuable Resources for AI-Enhanced Drug Discovery and Diagnostic Development

BioIVT’s ASTERAND® Human Tissue Repository contains clinical data from more than one million biospecimens and can be mined to reveal patterns and relationships in disease etiology and pathology.

QualityMetric’s SF-36v2 PRO Survey Contributes to EU’s ORCHESTRA SARS-CoV2 Impact Research

As we continue to navigate the SARS-CoV2 pandemic and new variants of the virus, there is an urgent need to understand how the disease and collective health responses affect the well-being of the general population. QualityMetric’s recent involvement in ORCHESTRA, an ambitious three-year international COVID research project led by the University of Verona. QualityMetric’s SF-36v2® patient-reported outcome (PRO) survey will be used to quantify the disease’s spectrum of symptoms and the functional health and well-being of patients from their own point of view. QualityMetric, a leading global clinical outcomes assessment (COA) solutions provider and scientific consultancy, is building upon our knowledge of the crisis through several COVID impact research initiatives. What makes this newsworthy: • Funded by the EU under the Horizon2020 ERAvsCORONA Action Plan, ORCHESTRA consists of thirty-seven partners from fifteen countries. • The SF-36v2® will help; quantify patient experiences, predict healthcare utilization and evaluate work productivity and job loss to determine COVID’s economic impact. • Researchers are increasingly using PRO measures to clarify the relationship between community disaster events and health-related quality of life. • PRO health surveys help stakeholders forecast health and economic outcomes from advanced predictive algorithms. The SF-36v2® health survey is one of QualityMetric’s most widely used global COA instruments. The data it collects across eight health domains will help the pan-European cohort take an evidence-based approach to developing recommendations for COVID-19 treatment and public health threat preparation.

Rho Named to Top Five Best Places to Work by Triangle Business Journal

CRO recognized among extra-large companies for its culture and flexible work environment during the pandemic Research Triangle Park, NC – September 14, 2021 - Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, has been honored as one of the top five 2021 Best Places to Work for companies with more than 350 employees by the Triangle Business Journal (TBJ), a multimedia source for local business news, research, and events in the Raleigh, Durham, Chapel Hill region of North Carolina, where Rho is headquartered. The Best Places to Work Awards is an annual program recognizing companies for creating policies and a work environment that employees value. The results are presented based upon employee survey feedback conducted by TBJ. Rho has won the award eight times since 2012.

Force Therapeutics Exceeds 110 Clinical Research Studies Published with Leading Medical Journals and Associations

Force Therapeutics Exceeds 110 Clinical Research Studies Published with Leading Medical Journals and Associations